Abpro stock soars after HER2 cancer therapy selected among top SITC abstracts By Investing.com
Update: 2025-11-04
Description
Abpro's experimental cancer therapy, CT-P72/ABP102, has been selected as a standout abstract for the upcoming Society for Immunotherapy of Cancer meeting. Co-developed with Celltrion, this bispecific antibody targets HER two-positive cancers, showing promising anti-tumor effects in lab studies. If successful in human trials, it could offer a new hope for patients with breast, gastric, and colorectal cancers that have resisted existing HER two treatments.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
